Hemofarm’s over-the-counter products (OTC) take the leading position in the pharmaceutical market of Serbia, with a share of 16.2%.
Hemofarm’s businness imperativ is the continuous improvement of its portfolio containing the latest generation of medicinal products, as well as the development of new segments, primarily in oncology.
Operation within the STADA Group opens additional possibilities for the sale of Hemofarm’s products in the highly demanding EU markets.
The Rx pharmaceutical market is conditioned by the pricing policy stipulated by the Ministry of Health and the Ministry of Trade. In that sense, the prices of medicinal products are also conditioned and officially approved values, which are determined by these two competent ministries.